Merck & Co.

pipeline pipes RD research
Biotech

Merck axes main asset from $1.9B Pandion buyout

MK-6194 was being studied in a pair of phase 2 trials for lupus and vitiligo. Merck picked up the asset from Pandion in a $1.9 billion acquisition.
Gabrielle Masson Jul 29, 2025 2:42pm
A chessboard with blocks that read MA

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova

Jul 15, 2025 10:16am
Realistic white price tags collection Special offer or shopping discount label

China biotechs ‘reshaping’ US biopharma: Jefferies report

Jul 14, 2025 2:30pm
Whale swimming in ocean seen from above

Merck wades deeper into HIV PrEP waters with pair of trials

Jul 14, 2025 1:12pm
Graphic showing arrows missing the bullseye on a target

How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble

Jun 13, 2025 8:00am
Coral reef sea underwater

Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3

Jun 9, 2025 9:00am